Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone Dosing in Poorly-Controlled Drug Naive T2DM
NCT00044460Phase 4Completed
- Sponsor
- GSK
- Start
- May 2002
- Primary completion
- Apr 2003
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of rosiglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Change in HbA1c from baseline at 24 weeks. Started May 2002; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00044460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044460.